SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Favrille, Inc. today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will present at the CIBC World Markets 16th Annual Healthcare Conference at 2:00 p.m. Eastern time on Wednesday, November 9, 2005. The conference will be held at the Waldorf-Astoria in New York City. Please note that attendance at the conference is by invitation only.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)
Dr. Longenecker will provide an overview of the Company and the clinical trials of its lead compound, FavId(R), for the treatment of B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until December 9, 2005.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.CONTACT: Tamara A. Seymour, CFO and Vice President, Finance &Administration, +1-858-526-8035, tseymour@favrille.com, or Pete De Spain,Associate Director, Investor Relations & Corporate Communications,+1-858-526-2426, pdespain@favrille.com, both of Favrille, Inc.
Web site: http://www.favrille.com/
